General information

Chinese Journal of Cancer Biotherapy (CJCB, ISSN 1007-385X, CN 31-1725/R) is co-sponsored by Chinese Immunology Association and Chinese Anti-cancer Association and founded in 1994. Being the only journal in its field in China, CJCB is listed as a national core journal and a source journal of Chinese Scientific Article Index. CJCB is an open access journal, published very two months.

The columns of CJCB include commentary, academician forum, expert forum, original article (basic and clinical research article), prompt report, case report, review article, etc. The target readers of CJCB include clinicians and researchers involved in tumor prevention and treatment, teachers and students of medical institutions, and other relevant researchers.

Editorial board members

Professor CAO Xue-tao, the chief editor of CJCB, is a top scientist of National Program on Key Basic Research Projects (973 Program) and national High-tech R&D Program (863 Program), a member of Chinese Academy of Engineering, the head of Chinese Immunology Association, and the head of National Key Laboratory of Medical Immunology.

The editorial board of CJCB is composed by 73 prestigious scientists home and abroad, including 11 academicians (Cao Xue-tao, Ba De-nian, Wu Meng-chao, Liu Xin-yuan, Wu Ming, Gu Jian-ren, Fan Dai-ming, Shen Bei-fen, Wei Yu-quan, Zeng Yi-xin, Chen Zhi-nan), 6 heads of national key laboratories, and 8 international board members from America and German.

Aim and Scope

CJCB is dedicated to report the laboratory and clinical breakthroughs in the field of cancer biotherapy in China, focusing on the new theories, new techniques, new methods and new drugs concerning the following areas: gene therapy of tumors, vaccine development, antibody treatment, small molecule targeted therapy, and immune cells and cytokine treatment, etc.

CJCB also publicizes the strategies and policies of Chinese government on cancer biotherapy, introduces the new development of cancer biotherapy in the world, and thus CJCB has become a showcase of scientific advancement in the area of cancer biotherapy in China, and an important flat for communication and cooperation between those involved in the area.

Peer reviewing

CJCB is a peer-reviewed journal with more than 260 reviewers from all over the country, including 10 from overseas. All the submitted manuscripts undergoes strict peer reviewing. Usually an article is reviewed by 2 peers. When there are quite different opinions by the 2 peers, a third peer is consulted. A statistician will be consulted for comment when an article involves too much statistics. After peer reviewing, a final decision will be made on an article by the editor board meeting based on the reviewers’ comments.

CJCB put more emphasis on the novelty and scientific quality of articles. Articles with one of the following problems will be rejected: (1) a repeat of previous findings; (2) experimental designing violates the basic rules such as randomness, controlled, blindness, etc.; (3) improper grouping; (4) unreliable model preparation and outdate techniques; (5) improper handling of data; (6) violation of experimental ethics; (7) failure in declaration of conflict of interest; (8) scientific misconduct, etc.. Manuscripts with major revision will be reviewed again by the reviewers before they can be accepted.

Coverage of CJCB by indexing systems abroad

CJCB is now covered by the following well-known indexing databases:

1) Chemical Abstracts (CA, USA);

2) Excerpta Medica Database (EMBASE, Netherland);

3) Cambridge Scientific Abstracts (CSA, USA);

4) Abstracts Journal (AJ, Russia);

5) Centre for Agriculture and Bioscience Abstract (CABA, Britain);

6) Index Copernicus (IC, Poland);

7) Global Health (GH, Britain);

8) Western Pacific Region Index Medicus (WPRIM,WHO);

Characteristics of journal

CJCB always takes academic level and scientific quality as its top priority. Great efforts are made to solicit contributions and to carry out strict peer reviewing, so as to continuously improve the overall quality of CJCB. The journal always publishes articles produced by top institutions in China in the field of cancer biotherapy.

In recent years, more than 70% of the articles published by CJCB were supported by the grants like the National Natural Science Foundation of China, “973 Program”, “863 Program”, and the Health Ministry Foundations. In every issue, we invite a prestigious scientist (including the board members) to write commentary or expert forum of a certain topic of cancer biotherapy. CJCB publishes monographic report, in which a number of articles focusing a certain topic are published in the same issue.

An article is published with an average period of 4.5 months; however, articles with new breakthroughs may be published within 2 months.

The format of articles in CJCB strictly abides by the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals"（ICMJE）, which is stated in the instructions for authors and practiced during copyediting, thus it can be assured that the format of CJCB meet the international standard. All the original articles are in the “IMRAD” format and have English abstracts, key words, table and figure headings, table of contents, copyright statement.

When a clinical trial is submitted, we require the authors register their study in Chinese Clinical Trial Registration and Publish Collaboration (ChiCTRPC) and attach the registration number on the manuscript submitted. Descriptions about randomness, controlling, and blindness in experimental design should be included in the manuscript. Ethical statement should also be included; authors are required to state clearly that their experiments are approved by the corresponding associations. Informed consent and the approval letter of ethical committees are required when human subjects or embryonic stem cells are involved in an article. We keep a close eye on the treatment of experimental animals. Proper treatment of experimental animals should be stated in the articles.

CJCB requires a list containing the contributions of each author of an article. CJCB always keep a close eye on potential scientific misconducts in articles submitted. A timely statement of withdrawing article will be made on CJCB whenever scientific misconducts are discovered. A statement of conflicts of interest is required for each submitted manuscript.

CJCB has been awarded as an Excellent Journal by Chinese Association of Science and Technology and an Excellent Journal by Shanghai Municipal Government. Now CJCB enjoys a high reputation in the field of oncology in China.

Contact information

Editorial office of Chinese Journal of Cancer Biotherapy

800 Shangying Rd

Yangpu District, Shanghai, 200433, China 

Editorial Office Tel: 86(21)-81871002-22

Editorial Office Fax: 86(21)-81871007

E-mail: cjcb@biother.org